Guggenheim Capital’s BioTelemetry, Inc. BEAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-25,082
| Closed | -$1.81M | – | 2210 |
|
|
2020
Q4 | $1.81M | Buy |
25,082
+8,960
| +56% | +$469K | 0.01% | 1012 |
|
|
2020
Q3 | $735K | Buy |
16,122
+3,609
| +29% | +$151K | 0.01% | 1329 |
|
|
2020
Q2 | $565K | Buy |
+12,513
| New | +$561K | ﹤0.01% | 1416 |
|
|
2018
Q4 | – | Sell |
-31,140
| Closed | -$2.01M | – | 2493 |
|
|
2018
Q3 | $2.01M | Buy |
31,140
+6,141
| +25% | +$343K | 0.01% | 1235 |
|
|
2018
Q2 | $1.13M | Sell |
24,999
-95,288
| -79% | -$3.8M | 0.01% | 1550 |
|
|
2018
Q1 | $3.73M | Buy |
120,287
+937
| +0.8% | +$30.8K | 0.01% | 1182 |
|
|
2017
Q4 | $3.57M | Sell |
119,350
-4,638
| -4% | -$134K | 0.01% | 1236 |
|
|
2017
Q3 | $4.09M | Buy |
123,988
+10,639
| +9% | +$368K | 0.01% | 1185 |
|
|
2017
Q2 | $3.79M | Sell |
113,349
-8,007
| -7% | -$239K | 0.01% | 1178 |
|
|
2017
Q1 | $3.51M | Sell |
121,356
-14,418
| -11% | -$357K | 0.01% | 1240 |
|
|
2016
Q4 | $3.04M | Buy |
135,774
+27,549
| +25% | +$539K | 0.01% | 1348 |
|
|
2016
Q3 | $2.01M | Buy |
+108,225
| New | +$2.04M | 0.01% | 1612 |
|
|
2014
Q3 | – | Sell |
-14,057
| Closed | -$101K | – | 3297 |
|
|
2014
Q2 | $101K | Buy |
14,057
+2,057
| +17% | +$16.4K | ﹤0.01% | 3007 |
|
|
2014
Q1 | $121K | Buy |
+12,000
| New | +$110K | ﹤0.01% | 2995 |
|
Other funds holding BEAT
Guggenheim Capital's BEAT Position: Q1 2021 in Review
Guggenheim Capital sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 25,082 shares — an estimated $1.81M sold.
Guggenheim Capital first reported a position in BEAT in Q1 2014 and held it in 14 quarters. The position peaked at $4.09M in Q3 2017. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.
- Guggenheim Capital reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
- Guggenheim Capital sold 25,082 BioTelemetry, Inc. shares in Q1 2021, an estimated $1.81M.
- Guggenheim Capital first reported a position in BioTelemetry, Inc. in Q1 2014 and held it in 14 quarters.
- Guggenheim Capital's BioTelemetry, Inc. position peaked at $4.09M in Q3 2017.
- 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.
Based on Guggenheim Capital's 13F filing for Q1 2021, filed 13 May 2021.